HSP90AB1 and breast carcinoma: The exogenous beta isoform of Hsp90 activates the formation of extracellular fibronectin in breast cancer cells, while knockdown or inhibition of Hsp90β leads to reduced deposition and can be partially rescued by the addition of exogenous Hsp90 (Hunter et al., 2014).